site stats

Evofem financials

WebApr 25, 2024 · Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the first quarter ended March 31, 2024 as follows: WebApr 14, 2024 · SAN DIEGO, April 14, 2024--Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced …

Evofem Biosciences (EVFM) Financial Statements: Income - Stock …

WebAug 4, 2024 · Evofem continues to expect net product sales in the range of $30 to $35 million for its 2024 fiscal year, representing 264% to 325% growth year-over-year. Gross … WebDescription. Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). saint ambrose catholic school houston texas https://stork-net.com

Evofem Biosciences Reports Fourth Quarter and Year-End …

Web6 minutes ago · SAN DIEGO , April 14, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. , (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2024.Reporting to Chief Executive Officer Saundra Pelletier … Web6 minutes ago · SAN DIEGO , April 14, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. , (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), … WebEvofem Biosciences, Inc., (OTCQB: EVFM) (the "Company") today announced it has implemented measures to lower its operating expenses, with the goal of reaching cash … thierry sauvageot

Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

Category:Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary

Tags:Evofem financials

Evofem financials

Evofem Biosciences Announces $10 Million Registered Direct Offering of ...

WebApr 6, 2024 · Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company, which develops and commercializes innovative products to unmet needs in women's … Web2 days ago · In the first quarter of 2024, Evofem gained Phexxi coverage for 16.3 million new lives from payers including Mississippi Medicaid, Indiana State Medicaid, multiple Blue Cross Blue Shield plans ...

Evofem financials

Did you know?

WebFinancials. Annual Quarterly ... Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing products to address unmet needs in women ... WebAug 4, 2024 · Evofem continues to expect net product sales in the range of $30 to $35 million for its 2024 fiscal year, representing 264% to 325% growth year-over-year. Gross-to-net is expected to be 40% or ...

WebMar 6, 2024 · Item 1.01 Entry into a Material Definitive Agreement. Securities Purchase Agreement. On March 13, 2024, Evofem Biosciences, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement ("SPA"), effective March 6, 2024, with certain investors (the "Investors") providing for the sale and issuance of senior … WebEvofem Biosciences Inc. SEC filings breakout by MarketWatch. View the EVFM U.S. Securities and Exchange Commission reporting information.

WebApr 6, 2024 · Get the detailed income statement for Evofem Biosciences, Inc. (EVFM). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue. WebEvofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%.

WebOct 12, 2024 · The securities described above are being offered and sold only by means of a written prospectus and related prospectus supplement forming part of Evofem's shelf registration statement on Form S-3 ...

WebMar 9, 2024 · Evofem Biosciences, Inc. Mar 09, 2024, 06:50 ET. SAN DIEGO, March 9, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim ... saint ambrose catholic school tucsonWebApr 10, 2024 · EVOFEM BIOSCIENCES, INC. ... The Company and each of its Subsidiaries maintains internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the 1934 Act) that is ... thierry sauzeWebMar 3, 2024 · In the fourth quarter of 2024, Evofem strengthened its balance sheet with $10 million in gross proceeds from the sale of Series B Convertible Preferred Stock to an … thierry sauvage tahitiWebApr 6, 2024 · Detailed financial statements for Evofem Biosciences (EVFM), including the income statement, balance sheet, and cash flow statement. ... Financials in millions USD. Fiscal year is January - December. Millions USD. Fiscal year is Jan - Dec. TTM. Millions. Export. Year 2024 2024 2024 2024 2024 2016 2015 2014 2013 2012; thierry sauvanetWebEVOFEM BIOSCIENCES, INC. EVOFEM BIOSCIENCES, INC. 0.42 ‎-5.94%. 0.42. at close ‎-0.03 (‎-5.94%) ... Financial Leverage. When assets to equity is a low ratio, it means the company has chosen ... thierry sauvaireWebGet the latest Evofem Biosciences Inc (EVFM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. thierry sauvigne lyonWebEvofem Biosciences Inc. Annual stock financials by MarketWatch. View the latest EVFM financial statements, income statements and financial ratios. thierry sauzeau passy